This company has been acquired
Global Blood Therapeutics Management
Management criteria checks 4/4
Global Blood Therapeutics' CEO is Ted Love, appointed in Jun 2014, has a tenure of 8.33 years. total yearly compensation is $8.19M, comprised of 8.7% salary and 91.3% bonuses, including company stock and options. directly owns 1.37% of the company’s shares, worth $63.19M. The average tenure of the management team and the board of directors is 6.5 years and 5.8 years respectively.
Key information
Ted Love
Chief executive officer
US$8.2m
Total compensation
CEO salary percentage | 8.7% |
CEO tenure | 8.3yrs |
CEO ownership | 1.4% |
Management average tenure | 6.5yrs |
Board average tenure | 5.8yrs |
Recent management updates
Recent updates
Global Blood Therapeutics expects to complete Pfizer deal in early October
Sep 30Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals
Sep 16Pfizer said to have had bidding war with Johnson & Johnson for Global Blood
Aug 24What Pfizer Is Getting Through The Acquisition Of Global Blood Therapeutics
Aug 08Global Blood Therapeutics to expand access to its sickle cell disease treatment in Brazil
Jul 14GBT begins phase 2/3 clinical trial of GBT601 to treat sickle cell disease
Jun 29Global Blood Therapeutics: Powerhouse Of The Future
Jun 21Global Blood Therapeutics (NASDAQ:GBT) Is Making Moderate Use Of Debt
Jun 07Global Blood Therapeutics: Hitting A Growth Inflection
Apr 12Global Blood Therapeutics: Changing My Strategy After Recent Earnings
Mar 12Is Global Blood Therapeutics (NASDAQ:GBT) Using Too Much Debt?
Feb 24Global Blood Therapeutics: Revisiting A Stellar Grower
Dec 25IBI Research On Global Blood Therapeutics: Galvanized For Growth
Nov 30Despite Lacking Profits Global Blood Therapeutics (NASDAQ:GBT) Seems To Be On Top Of Its Debt
Nov 03Global Blood Therapeutics: It Might Be Time To Buy The Dip
Oct 24Global Blood Therapeutics: Attempting To Classify The Investment
Aug 07Global Blood Therapeutics (NASDAQ:GBT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jul 08Shareholders May Not Be So Generous With Global Blood Therapeutics, Inc.'s (NASDAQ:GBT) CEO Compensation And Here's Why
Jun 12Global Blood Therapeutics announces employment inducement grants
Jun 04Global Blood Therapeutics: Increasing Specialization In SCD
May 09Is Global Blood Therapeutics (NASDAQ:GBT) A Risky Investment?
Mar 18Breakeven On The Horizon For Global Blood Therapeutics, Inc. (NASDAQ:GBT)
Feb 20Did Business Growth Power Global Blood Therapeutics' (NASDAQ:GBT) Share Price Gain of 152%?
Jan 25Have Insiders Been Buying Global Blood Therapeutics, Inc. (NASDAQ:GBT) Shares?
Dec 29CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Jun 30 2022 | n/a | n/a | -US$322m |
Mar 31 2022 | n/a | n/a | -US$310m |
Dec 31 2021 | US$8m | US$716k | -US$303m |
Sep 30 2021 | n/a | n/a | -US$277m |
Jun 30 2021 | n/a | n/a | -US$266m |
Mar 31 2021 | n/a | n/a | -US$249m |
Dec 31 2020 | US$18m | US$661k | -US$248m |
Sep 30 2020 | n/a | n/a | -US$282m |
Jun 30 2020 | n/a | n/a | -US$286m |
Mar 31 2020 | n/a | n/a | -US$291m |
Dec 31 2019 | US$10m | US$597k | -US$267m |
Sep 30 2019 | n/a | n/a | -US$220m |
Jun 30 2019 | n/a | n/a | -US$199m |
Mar 31 2019 | n/a | n/a | -US$182m |
Dec 31 2018 | US$10m | US$569k | -US$174m |
Sep 30 2018 | n/a | n/a | -US$166m |
Jun 30 2018 | n/a | n/a | -US$152m |
Mar 31 2018 | n/a | n/a | -US$135m |
Dec 31 2017 | US$8m | US$520k | -US$117m |
Sep 30 2017 | n/a | n/a | -US$103m |
Jun 30 2017 | n/a | n/a | -US$95m |
Mar 31 2017 | n/a | n/a | -US$89m |
Dec 31 2016 | US$1m | US$479k | -US$82m |
Sep 30 2016 | n/a | n/a | -US$71m |
Jun 30 2016 | n/a | n/a | -US$65m |
Mar 31 2016 | n/a | n/a | -US$58m |
Dec 31 2015 | US$2m | US$438k | -US$51m |
Compensation vs Market: Ted's total compensation ($USD8.19M) is about average for companies of similar size in the US market ($USD6.59M).
Compensation vs Earnings: Ted's compensation has been consistent with company performance over the past year.
CEO
Ted Love (63 yo)
8.3yrs
Tenure
US$8,193,309
Compensation
Dr. Ted W. Love, M.D., serves as Independent Director at Royalty Pharma plc since July 30, 2020. He serves as Director of Seagen Inc. (formerly known as Seattle Genetics, Inc.). since August 2020. He serve...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 8.3yrs | US$8.19m | 1.37% $ 63.2m | |
CFO & Principal Accounting Officer | 6.5yrs | US$2.76m | 0.040% $ 1.8m | |
Chief Business & Strategy Officer | 7.5yrs | US$2.73m | 0.37% $ 17.2m | |
Chief Commercial Officer | 4.6yrs | US$2.75m | 0.084% $ 3.9m | |
Executive VP and Head of Research & Development | 1.4yrs | US$2.98m | 0.0089% $ 409.5k | |
Founder & Advisor | 11.8yrs | no data | no data | |
Founder & Advisor | 11.8yrs | no data | no data | |
Founder & Advisor | 11.8yrs | no data | no data | |
Executive Vice President of Operations | 2.5yrs | no data | 0.062% $ 2.9m | |
Senior Director of Corporate Communications & Investor Relations | no data | no data | no data | |
Chief Legal Officer & Secretary | 6yrs | US$5.93m | 0.064% $ 3.0m | |
Senior VP & Head of Corporate Communications | 3.8yrs | no data | no data |
6.5yrs
Average Tenure
60yo
Average Age
Experienced Management: GBT's management team is seasoned and experienced (6.5 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 9.1yrs | US$8.19m | 1.37% $ 63.2m | |
Lead Independent Director | 7.5yrs | US$348.28k | 0.056% $ 2.6m | |
Independent Director | 4.8yrs | US$320.78k | 0.017% $ 783.3k | |
Independent Director | 2.4yrs | US$313.28k | 0.013% $ 618.8k | |
Independent Director | 6.7yrs | US$318.28k | 0.039% $ 1.8m | |
Independent Director | 7.1yrs | US$310.78k | 0.013% $ 623.9k | |
Independent Director | 6.8yrs | US$333.28k | 0.0098% $ 454.8k | |
Independent Director | 3.8yrs | US$316.36k | 0.0080% $ 368.3k | |
Advisor & Director Emeritus | less than a year | US$308.28k | 0.058% $ 2.7m | |
Independent Director | 1.6yrs | US$735.61k | 0.0049% $ 226.5k |
5.8yrs
Average Tenure
66yo
Average Age
Experienced Board: GBT's board of directors are considered experienced (5.8 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/10/05 03:34 |
End of Day Share Price | 2022/10/04 00:00 |
Earnings | 2022/06/30 |
Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Global Blood Therapeutics, Inc. is covered by 25 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Jason Matthew Gerberry | BofA Global Research |
John Newman | Canaccord Genuity |
Elemer Piros | Cantor Fitzgerald & Co. |